Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus

Antiviral Research

Volumn 48, Issue 2, 2000, Pages 117-124

  Ying, C ^a   De Clercq, E ^a   Neyts, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HBV; Mycophenolic acid; Ribavirin; Transplantation

Indexed keywords

3' FLUORODIDEOXYGUANOSINE; DIAMINOPURINE DIOXOLANE; DNA POLYMERASE; LOBUCAVIR; MYCOPHENOLIC ACID; NUCLEOSIDE ANALOG; PENCICLOVIR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; DNA SYNTHESIS; DRUG POTENTIATION; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL;

ACYCLOVIR; ANTIVIRAL AGENTS; CELL LINE; DIDEOXYNUCLEOSIDES; DIOXOLANES; DRUG SYNERGISM; GUANINE; GUANOSINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MYCOPHENOLIC ACID; PURINE NUCLEOSIDES; RIBAVIRIN; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 0033645403     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00121-2     Document Type: Article

References (27)

1. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration
2. Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys
3. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription
4. Perspectives for the treatment of hepatitis B virus infections
5. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
6. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
7. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells
8. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication
9. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
10. 2',3'-dideoxy-3'-fluoroguanosine inhibits duck hepatitis B virus in vivo
11. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir
12. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
13. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil
14. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1α, 2β, 3α)]-9-[2,3-bis(hydroxymethyl)-cyclo-butyl]guanine against different herpes viruses
15. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
16. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
17. Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro
18. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
19. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
20. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
21. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
22. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
23. Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation
24. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase
25. Therapy of chronic hepatitits B virus infection: inhibition of the viral polymerase and other antiviral strategies